Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma

Within one year, five immunotherapies have been approved for the treatment of patients with locally advanced or metastatic urothelial cancer. The availability of these immunotherapies brings challenges to all stakeholders in the field. Additional research is needed to identify biomarkers that are pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Yang‐Min, Maher, V. Ellen, Beaver, Julia A., Goldberg, Kirsten B., Blumenthal, Gideon M., Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813751/
https://www.ncbi.nlm.nih.gov/pubmed/29180460
http://dx.doi.org/10.1634/theoncologist.2017-0415
_version_ 1783300229766840320
author Ning, Yang‐Min
Maher, V. Ellen
Beaver, Julia A.
Goldberg, Kirsten B.
Blumenthal, Gideon M.
Pazdur, Richard
author_facet Ning, Yang‐Min
Maher, V. Ellen
Beaver, Julia A.
Goldberg, Kirsten B.
Blumenthal, Gideon M.
Pazdur, Richard
author_sort Ning, Yang‐Min
collection PubMed
description Within one year, five immunotherapies have been approved for the treatment of patients with locally advanced or metastatic urothelial cancer. The availability of these immunotherapies brings challenges to all stakeholders in the field. Additional research is needed to identify biomarkers that are predictive of individual patient response to different immunotherapies.
format Online
Article
Text
id pubmed-5813751
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-58137512018-02-21 Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma Ning, Yang‐Min Maher, V. Ellen Beaver, Julia A. Goldberg, Kirsten B. Blumenthal, Gideon M. Pazdur, Richard Oncologist Editorial Within one year, five immunotherapies have been approved for the treatment of patients with locally advanced or metastatic urothelial cancer. The availability of these immunotherapies brings challenges to all stakeholders in the field. Additional research is needed to identify biomarkers that are predictive of individual patient response to different immunotherapies. AlphaMed Press 2017-11-27 2018-02 /pmc/articles/PMC5813751/ /pubmed/29180460 http://dx.doi.org/10.1634/theoncologist.2017-0415 Text en Published 2017. This article is a U.S. Government work and is in the public domain in the USA
spellingShingle Editorial
Ning, Yang‐Min
Maher, V. Ellen
Beaver, Julia A.
Goldberg, Kirsten B.
Blumenthal, Gideon M.
Pazdur, Richard
Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
title Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
title_full Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
title_fullStr Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
title_full_unstemmed Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
title_short Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
title_sort accelerating early access to immunotherapies for advanced urothelial carcinoma
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813751/
https://www.ncbi.nlm.nih.gov/pubmed/29180460
http://dx.doi.org/10.1634/theoncologist.2017-0415
work_keys_str_mv AT ningyangmin acceleratingearlyaccesstoimmunotherapiesforadvancedurothelialcarcinoma
AT mahervellen acceleratingearlyaccesstoimmunotherapiesforadvancedurothelialcarcinoma
AT beaverjuliaa acceleratingearlyaccesstoimmunotherapiesforadvancedurothelialcarcinoma
AT goldbergkirstenb acceleratingearlyaccesstoimmunotherapiesforadvancedurothelialcarcinoma
AT blumenthalgideonm acceleratingearlyaccesstoimmunotherapiesforadvancedurothelialcarcinoma
AT pazdurrichard acceleratingearlyaccesstoimmunotherapiesforadvancedurothelialcarcinoma

Ejemplares similares